| 341 | 10 | 17 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:通过检测慢性心力衰竭患者外周血单核细胞(peripheral blood mononuclear cells,PBMCs NLRP3信号通路的表达水平,探讨NLRP3信号通路和其诱导的炎症反应在不同类型慢性心力衰竭患者的PBMCs中的表达。方法:选择本院2018年10月～2019年12月收治的Ⅱ、Ⅲ、Ⅳ级慢性心衰患者(NYHAⅡ～Ⅳ级)各20例为Ⅱ、Ⅲ、Ⅳ组,选择20名健康人为对照组。采集所有受试者外周静脉血,分别提取血浆和单核细胞,磁珠分选法鉴定单核细胞,运用实时荧光定量聚合酶链反应(qRT-PCR)和蛋白质免疫印迹(Western blot)法检测PBMCs中NLRP3、ASC、Caspase-1的mRNA和蛋白的表达水平,酶联免疫吸附(ELISA)法检测血浆中白细胞介素-1β(IL-1β)的水平。结果:与对照组比较,Ⅱ、Ⅲ、Ⅳ组PBMCs中NLRP3、ASC、Caspase-1蛋白表达与mRNA水平增高(P<0.05),与Ⅱ组比较,Ⅲ、Ⅳ组这些指标的表达增加(P<0.05),与Ⅲ组比较,Ⅳ组这些指标的表达增加(P<0.05)。与对照组比较,Ⅱ、Ⅲ、Ⅳ组血浆中的IL-1β水平增高(P<0.05),与Ⅱ组比较,Ⅲ、Ⅳ组IL-1β表达增加(P<0.05),与Ⅲ组比较,Ⅳ组IL-1β表达增加(P<0.05)。结论:NLRP3-ASC-Caspase-1信号通路可能引起心力衰竭患者体内的慢性炎症并在慢性心力衰竭病情进展中发挥作用。
Abstract：Objective:To detect the expression of NLRP3 signal pathway in peripheral blood mononuclear cells(PBMCs of patients with chronic heart failure,and to explore the expression of NLRP3 signal pathway and its induced inflammatory response in PBMCs of patients with different types of chronic heart failure. Methods:Patients with chronic heart failure(NYHA Ⅱ～ Ⅳ),admitted to our hospital from 2019 to 2020 were included. The paatients mere divided into groups,including the Ⅱ group,the Ⅱ group and the Ⅳ group according to NYHA classification,and 20 normal subjects were selected as the control group. The peripheral venous blood of all subjects was collected,and the plasma and monocytes were extracted,respectively. The monocytes were identified by magnetic beads sorting. The mRNA and protein expression levels of NLRP3,ASC and Caspase-1 in PBMCs were detected by real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)and Western blot,and the level of interleukin-1 β（IL-1 β）in plasma was detected by enzyme-linked immunosorbent assay(ELISA). Results:Compared with the control group,the expression of NLRP3,ASC,Caspase-1 protein and mRNA in PBMCs of patients with grade Ⅱ,Ⅲ and Ⅳ increased. Compared with patients with grade Ⅱ,the expression of these indexes increased in patients with grade Ⅲ and Ⅳ. Compared with patients with grade Ⅲ,the expression of these indexes increased in patients with grade Ⅳ. Compared with the control group,the plasma levels of IL-1 β in patients with grade Ⅱ,Ⅲ and Ⅳ were higher than those in patients with grade Ⅱ,Ⅲ and Ⅳ（P<0.05）. The expression of these indexes in patients with grade Ⅲ and Ⅳ was higher than that in patients with grade Ⅲ（P<0.05）.Conclusion:The results suggest that NLRP3-ASC-Caspase-1 signal pathway may cause chronic inflammation in patients with heart failure and play a role in the progression of chronic heart failure.
1 Eslick GD,Thampan BV,Nalos M,et al. Circulating interleukin-18 concentrations and a loss-of-function P2X7polymorphism in heart failure[J]. Int J Cardiol,2009,137(1):81-83.
2 An Tassell B,Varma A,Salloum FN,et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice[J]. Cardiovasc Pharmacol,2010,22:117-122.
3 邢作英，王永霞，朱明军.慢性心力衰竭流行病学研究现状及其病因[J].中华实用诊断与治疗杂志，2012,22(10):937-938.
4 Suetomi T,Miyamoto S,Brown JH. Inflammation in nonischemic heart disease:Initiation by cardiomyocyte CaMKⅡand NLRP3 inflammasome signaling[J]. Am J Physiol Heart Circ Physiol,2019,317:H877-H890.
5 Bracey NA,Beck PL,Muruve DA,et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β[J]. Exp Physiol,2013,98(2):462-472.
6 Mezzaroma E,Toldoa S,Farkasb D,et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse[J]. PNAS,2011,108(49):19725-19730.
7 Kawaguchi M,Takahashi M,Hata T,et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury[J]. Circulation,2011,123:594-604.
8 Elahi M,Asopa S,Matata B. NO-cGMP and TNF-αcounter regulatory system in blood:Understanding the mechanisms leading to myocardial dysfunction and failure[J]. Biochim Biophys Acta,2010,1772:5-14.
9 Vaduganathan M,Greene SJ,Butler J,et al. The immunological axis in heart failure:Importance of the leukocyte differential[J]. Heart Fail Rev,2013,18(6):835-845.
10 Kanneganti TD,Lamkanfi M,Nunez G. Intracellular NOD-like receptors in host defense and disease[J]. Immunity,2007,27:549-559.
11 Abbate A,Kontos MC,Grizzard JD,et al. Interleukin-1 blockade with Anakinra to prevent adverse cardiac remodeling after acute myocardial infarction(Virginia Commonwealth University Anakinra Remodeling Trial[VCU-ART]pilot study)[J].Am J Cardiol,2010,105:1371-1377.
12 Abbate A,Van Tassell BW,Biondi-Zoccai G,et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction from the Virginia Commonwealth University-Anakinra Remodeling Trial(2)(VCU-ART2)pilot study[J]. Am J Cardiol,2013,111(10):1394-1400.
13 Arend WP,Palmer G,Gabay C. IL-1,IL-18,and IL-33 families of cytokines[J]. Immunol Rev,2008,223:20-38.
14 Dinarello CA. Interleukin-18[J]. Methods, 1999,19(1):121-132.
15 Lamkanfi M,Dixit VM. Inflammasomes and their roles in health and disease[J]. Annu Rev Cell Dev Biol,2012,28:137-161.
16 Fedak PWM,Verma S,Weisel RD,et al. Cardiac remodeling and failure. From molecules to man(part 1)[J]. Cardiovasc Pathol,2005,14:1-11.
17 Toldo S,Kannan H,Bussani R,et al. Formation of the inflammasome in acute myocarditis[J]. Int J Cardiol,2014,171(3):e119-e121.
18 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018,46(10):760-789.
19 Van LS,Tsch?pe C. Inflammation-cause or consequence of heart failure or both[J]. Curr Heart Fail Rep,2017,14:251-265.
20 Dhondup YC,Sjaastad I,Scott H,et al. Sustained toll-like receptor 9 activation promotes systemic and cardiac inflammation,and aggravates diastolic heart failure in SERCA2a KO mice[J]. PLoS One, 2015, 10:e0139715.
21 Chen YY,Li RS,Wang ZL,et al. Dehydrocostus lactone inhibits NLRP3 inflammasome activation by blocking ASC oligomerization and prevents LPS-mediated inflammation in vivo[J]. Cell Immunol, 2020, 349:104046.
22 Luheshi NM,Giles JA,Lopez-Castejon G,et al. Sphingosine regulates the NLRP3-inflammasome and IL-1βrelease from macrophages[J]. Eur J Immunol,2012,42,716-725.
23 Cai C,Zhu XW,Li PZ,et al. NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid[J]. Inflammation,2017,40:1875-1883.
24 Martinon F,Pétrilli V,Mayor A,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature,2006,440,237-241.
25 Hirota SA,Ng J,Lueng A,et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis[J]. Inflamm Bowel Dis,2011,17(6):1359-1372.
26 Schroder K,Zhou R,Tschopp J. The NLRP3 inflammasome:A sensor for metabolic danger[J]. Science,2010,327,296-300.
27 Vilaysane A,Chun J,Seamone ME,et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD[J]. J Am Soc Nephrol,2010,21,1732-1744.
28 Ralston JC,Lyons CL,Kennedy EB,et al. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues[J]. Annu Rev Nutr, 2017, 37:77-102.
29 Packer M. The neurohormonal hypothesis:A theory to explain the mechanism of disease progression in heart failure[J]. J Am Coll Cardiol,1992,20(1):248-254.
30 Seta Y,Shan K,Bozkurt B,et al. Basic mechanisms in heart failure:The cytokine hypothesis[J]. J Card Fail,1996,2(3):243-249.
31 Chung ES, Packer M, Lo KH. Randomized, double-blind,placebo-controlled,pilot trial of Infliximab,a chimeric monoclonal antibody to tumor necrosis factor-α，in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against cognestive heart failure(ATTACH)trial[J]. Circulation, 2003, 107:3133-3140.
32 El-Menyar AA. Cytokines and myocardial dysfunction:state of the art[J]. J Card Fail,2008,14(1):61-74.
33 Hofmann U,Frantz S. How can we cure a heart“in flame”? A translational view on inflammation in heart failure[J]. Basic Res Cardiol,2013,108:356-375.
34 Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol,2009,27:519-550.
35 Dinarello CA. A clinical perspective of IL-1b as the gatekeeper of inflammation[J]. Eur J Immunol,2011,41:1203-1217.
36 Van Tassell B,Seropian IM,Toldo S,et al. Interleukin-1b induces a reversible cardiomyopathy in the mouse[J]. Inflamm Res,2013,62:637-640.
37 Van Tassell B,Arena RA,Toldo S,et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure[J]. PLoS One,2012,7 (3):e33438.
38 Pomerantz BJ,Reznikov LL,Harken AH,et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β[J]. Proc Natl Acad Sci USA,2001,98(5):2871-2876.
39 Kawaguchi M,Takahashi M,Hata T,et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury[J]. Circulation,2011,123:594-604.
40 Diaz-Ca?estro C,Reiner MF,Bonetti NR,et al. AP-1(Activated Protein-1)transcription factor JunD regulates ischemia/reperfusion brain damage via IL-1β（Interleukin-1β）[J]. Stroke,2019,50:469-477.
基本信息:
DOI：10.13210/j.cnki.jhmu.20201209.002
中图分类号:R541.6
引用信息:
[1]朱飞宇,徐庆梅,朱建,等.NLRP3-ASC-Caspase-1信号通路在慢性心力衰竭患者外周血单核细胞中的表达[J].海南医学院学报,2021,27(14):1052-1058.DOI:10.13210/j.cnki.jhmu.20201209.002.
基金信息:
国家自然科学基金资助项目（81770297、81970313）; 安徽省自然科学基金资助项目（1908085QH353）; 安徽省教育厅重大项目（KJ2018ZD023）; 蚌埠医学院自然科学基金重点项目（BYKY1833ZD）~~
2020-12-10
2020-12-10
2020-12-10